Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Benchtop Mass Spectrometers

By Drug Discovery Trends Editor | May 25, 2010

Waters Corporation introduced two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).

The Xevo TQ-S and Xevo G2 QTof are the newest members of the Xevo family of benchtop mass spectrometers first introduced in 2008 and are the most powerful mass spectrometers in their class. Combined with Waters ACQUITY UltraPerformance LC (UPLC) Systems these mass spectrometers offer scientists an unequalled combination of separations power with highest levels of sensitivity whether for compound identification, quantification, and screening, or for extracting the most information from the smallest sample volumes all in a single analysis.

Said Brian Smith, V.P. Mass Spectrometry Operations, Waters Division, “With today’s announcements, Waters has firmly established its leadership position in high-performance mass spectrometry. The new features and innovations scientists will find in our new Xevo mass spectrometers, more than anything else, are intended to deliver results. As they have told us time and again, that’s what really counts.”

At a press conference, Waters global Vice President of Worldwide Marketing, Dr. Rohit Khanna, remarked, “Our customers have told us they want high-quality, high-impact results faster, and with less effort. These new additions to our Xevo family of mass spectrometers mean we can deliver applications-specific UPLC/MS/MS systems that can help them achieve their scientific and business objectives and put answers to complex challenges within easy reach.”

Waters expects to begin shipping the Xevo G2 QTof system in June and the Xevo TQ-S system in September.

Waters Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE